Abstract library

766 results for "systemic therapy".
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1670 A Successful Case of Controlling the Multiple Distant Metastasis of Pancreatic G2 NET with Local Therapy Combined with Systemic Pharmacotherapy
Introduction: Several systemic pharmacotherapies could be applied to multiple metastatic pancreatic neuroendocrine tumor (PNET). However, we have not determined how to coordinate ‘local’ therapy such as salvage surgery and transarterial chemoembolization with systemic pharmacotherapies for these multiple metastatic PNET.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Yuichiro Uchida
Authors: Uchida Y, Masui T, Kenzo N, Asahi S, ...
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...
#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)
Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Jaroslaw Ćwikła
#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: PhD Paula Jimenez-Fonseca
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1899 Sequence of Therapy and Survival among Advanced Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Therapy for advanced pNETs involves surgery (SG) and non-SG options, including liver ablation (ABL), systemic therapy (ST), somatostatin analogues (SSA). Optimal initial therapy is unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Erica Tsang
Authors: Tsang E, Speers C, Cheung W, Kennecke H, ...
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System
Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: MD Tomohiro Yamaguchi
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.